Associations of PD-L1, PD-L2, and HLA class I expression with responses to immunotherapy in patients with advanced sarcoma: post hoc analysis of a phase 1/2 trial

Miwa, Shinji; Nojima, Takayuki; Alomesen, Avelino; Ikeda, Hiroko; Yamamoto, Norio; Nishida, Hiroyuki; Hayashi, Katsuhiro; Takeuchi, Akihiko; Igarashi, Kentaro; Higuchi, Takashi; Yonezawa, Hirotaka; Araki, Yoshihiro; Morinaga, Sei; Asano, Yohei; Tsuchiya, Hiroyuki

doi:10.1007/s12094-021-02559-z

Cited by 2 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The functions of programmed death-1 receptor ligand 2 (PD-L2) in the immune response are not clear. PD-L2 is a target of interest in cancer and is expressed in sarcomas [23]. Sarcoma tissues showed the second highest expression of PD-L2 compared to all other cancer types based on our TCGA analysis (Figure 5).…”

Section: Pd-l2 Expression Levels Are High In Soft Tissue Sarcomasmentioning

confidence: 87%

Landscape of Immune-Related Markers and Potential Therapeutic Targets in Soft Tissue Sarcoma

Roszik

Mustachio

Livingston

et al. 2021

Cancers

View full text Add to dashboard Cite

Soft tissue sarcomas, depending on the subtype and grade, frequently recur and become metastatic after localized treatment. There is now great interest in applying immunotherapy to sarcomas to immuno-profile the different subtypes and immune monitor for prognosis. Our group previously showed that key immunotherapy target genes are present in sarcomas. Here, we extend our findings by demonstrating that sarcomas with a relatively high mutational load are likely to be more sensitive to immunotherapy compared to sarcomas with a lower mutation load. We also show that sarcomas with a higher mutation load are associated with the expression of key immune-related genes. We found that CD8+ T cells are present in sarcoma subtypes and that PD-L2 is highly expressed. These findings further define potential mechanisms behind the immunotherapy response of specific sarcoma subtypes and can be used to develop more optimal treatments in the future.

show abstract

Section: Pd-l2 Expression Levels Are High In Soft Tissue Sarcomasmentioning

confidence: 87%